Concurrent Boost with Adjuvant Breast Hypofractionated Radiotherapy and Toxicity Assessment
Background: The use of shorter radiotherapy schedules has an economic and logistic advantage for radiotherapy departments, as well as a high degree of patient convenience. The aim of this study is to assess the acute and short-term late toxicities of a hypofractionated radiotherapy schedule with...
Main Authors: | Mona M. Sayed, Mohamed I. El-Sayed, Alia M. Attia, Mostafa E. Abdel-Wanis |
---|---|
Format: | Article |
Language: | English |
Published: |
Shiraz University of Medical Sciences
2015-01-01
|
Series: | Middle East Journal of Cancer |
Subjects: | |
Online Access: | http://mejc.sums.ac.ir/index.php/mejc/article/view/174/179 |
Similar Items
-
Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials
by: Charlotte Pfaffendorf, et al.
Published: (2022-08-01) -
Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: A systematic literature review
by: Martin Schmitt, et al.
Published: (2022-08-01) -
Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
by: Lee Dong, et al.
Published: (2012-06-01) -
Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer
by: Angel Montero, et al.
Published: (2023-07-01) -
Outcome of hypofractionated breast irradiation and intraoperative electron boost in early breast cancer: A randomized non‐inferiority clinical trial
by: Pedram Fadavi, et al.
Published: (2021-10-01)